摘要
近年来,妊娠期糖尿病(GDM)患病率显著升高,引发产妇及其子代多种不良结局,而早期诊断和良好控制血糖可显著改善妊娠结局。目前,GDM诊断主要依据口服葡萄糖耐量试验(OGTT),但临床应用时存在诸多不足。新型生物学标志物糖基化CD59是一种补体调节蛋白的糖基化产物,可在体液中稳定存在,与血糖水平呈线性相关,具有测试简便、可重复性佳等优点,且已开发出可稳定使用的试剂盒,在GDM的早期诊断、标准诊断和妊娠结局预测等方面均显示出良好的价值。
In recent years,the prevalence of gestational diabetes mellitus(GDM) has significantly increased,leading to various adverse outcomes for mothers and their offspring.Early diagnosis and good blood glucose control can significantly improve pregnancy outcomes.Currently,the diagnosis of GDM mainly relies on the oral glucose tolerance test(OGTT),but there are many limitations in clinical application.The new biological marker glycosylated CD59 is a glycosylation product of complement regulatory proteins that can stably exist in body fluids and is linearly related to blood glucose levels,which has the advantages of simple testing and good reproducibility,and has been developed into a stable reagent kit.It has shown good value in the early diagnosis,standard diagnosis,and prediction of pregnancy outcomes of GDM.
作者
王婉莹
陆小凡
徐冲
张瑛
邹会玲
孙宇
WANG Wanying;LU Xiaofan;XU Chong;ZHANG Ying;ZOU Huiling;SUN Yu(Postgraduate School of Xuzhou Medical University,Xuzhou,Jiangsu,221004;Department of Endocrinology,Suqian Hospital Affiliated to Xuzhou Medical University,Suqian,Jiangsu,223800)
出处
《实用临床医药杂志》
CAS
2024年第4期145-148,共4页
Journal of Clinical Medicine in Practice
基金
江苏省卫健委科研课题面上项目(M2020094)
江苏省宿迁市重点研发项目(S202211)。
关键词
妊娠期糖尿病
糖基化CD59
精准诊断
妊娠结局
生物标志物
血糖
gestational diabetes mellitus
glycosylated CD59
precise diagnosis
pregnancy outcomes
biomarker
blood glucose
